Stocks under $1 can bring big gains. But, you have to find the right ones. And the world of stocks can seem daunting. Especially when some cost hundreds or even thousands of dollars per share. But, there are many stocks under $1 that can be just as fun and rewarding to invest in.

At first glance, stocks under $1 may seem like a risky investment choice. But, there are several key factors that make these stocks a great option.

One factor is their potential for high returns. Stocks under $1 are often overlooked by many investors. So, they can be more volatile than stocks in other price ranges. But, do some careful research and due diligence. These stocks can offer big gains that far outpace more expensive stocks.

Another key factor is the potential for dividends. Many stocks under $1 have high dividend yields. Which means they pay a significant part of profits in dividends to investors. This can help ensure consistent returns on your investment. Even if the stock price fluctuates.

Of course, not all stocks under $1 will be winners. There are some important considerations to keep in mind. When investing in these stocks, you need to think about certain factors. This includes evaluating the company’s financial health, and doing your homework on market trends for that particular sector or industry. But with careful planning and research, there’s no reason why you can’t invest in stocks under $1. And enjoy great success with them too!

Stocks Under $1 in 2022

No. 4 Cidara Therapeutics (Nasdaq: CDTX)

Cidara Therapeutics is a promising stock under $1. And it has been gaining traction in the biotech world. Founded in 2012, Cidara is focused on developing new treatments for infections. Specifically, those caused by deadly pathogens. Including antibiotic-resistant strains of bacteria.

Cidara has a growing pipeline of products in development. And a strong track record of success. So, they make for an exciting company to watch in the biotech industry. And shares are currently trading for cheap. So, it offers investors an opportunity to invest in promising stocks under $1. And potentially reap big gains over time.

If you’re looking for stocks under $1 to invest in, don’t overlook Cidara Therapeutics. This up-and-coming biotech company could be a great choice. Especially for investors looking to get in on the ground floor of a stock with big potential.

No. 3 Applied Genetics Technologies (Nasdaq: AGTC)

Applied Genetics Technologies (AGTC) is a biotech company. The company specializes in the development of cutting-edge genetic therapies. And they do so for a variety of rare diseases and conditions. With stocks currently trading below $1, AGTC is an attractive investment opportunity. Specifically, for investors looking to capitalize on the potential of this biotech company.

AGTC has developed several groundbreaking genetic therapies over the years, including treatments for blindness and rare blood disorders. And these technologies have shown great promise in clinical trials. Because they’ve been demonstrating their ability to significantly improve patients’ health outcomes. And their quality of life.

AGTC has struggled to gain traction in the public markets. This is partly due to competition from larger companies in the biotech space. And that’s despite its success in developing these novel genetic therapies. However, stocks are currently trading at a low price. So, now may be the perfect time to invest in this innovative biotech company. If you’re looking for stocks under $1 that are promising and have high growth potential, watch AGTC.

[gated-content list=’INVESTME’ headline=’Keep Reading This Article and Find Out the Top 2 Stocks Under $1 to Buy Now’ body=’

Enter your email below to read the reveal the top two stocks under $1.

You’ll also be opted in to receive our free daily e-letter, Investment U, where you’ll find expert investment insight, analysis and stock picks for all the best investment opportunities.

‘ button=’Unlock The Rest’ mvid=’1516177′ coreg=’274702′]

No. 2 ProQR Therapeutics (Nasdaq: PRQR)

ProQR Therapeutics is a clinical stage biotech company. They focus on the development of RNA-based therapies. Specifically, for the treatment of rare genetic disorders. And the company’s most advanced product candidate, Sepofarsen, is a promising solution. It could eventually treat Leber’s congenital amaurosis type 10 (LCA10). It’s a disease that leads to blindness, typically in children.

The company has seen strong interest in Sepofarsen from both patients and investors. And its stocks under $1 have been on a tear in recent months. Shares of ProQR have had strong spikes of over 500% in the past. So, it’s showing good signs of future success.

And ProQR still has a long way to go before Sepofarsen is approved and on the market. But, it’s getting closer. Recently, they’ve announced strong results for Phase two out of three of clinical trials. So, there are two things that make it a compelling investment. One, the company’s strong performance in clinical trials. And two, the significant unmet need for treatments for rare genetic disorders.

No. 1 Cybin, Inc. (NYSE: CYBN)

Stocks under $1 come in all forms. Cybin is a clinical stage pharmaceutical company that develops psychedelics for therapeutic purposes. Their mission is to provide patients with access to innovative, evidence-based psychedelic medicines. Cybin is advancing a broad portfolio of product candidates in various therapeutic areas. This includes mental health and neurological disorders.

CBD is fast becoming a normal form of treatment for many health issues. So, scientists are reaching out to more non-traditional forms of treatment. This stock under $1 has products that are based on natural compounds. And these compounds have provided for centuries in traditional medicine. Specifically for their hallucinogenic properties. They are thought to work by modulating serotonin levels in the brain, which can impact mood, cognition and perception.

And they have become a class of drugs that have the potential to treat a wide range of mental health conditions. This includes depression, anxiety, PTSD and addiction. But despite their therapeutic potential, there are still a lot of questions. Especially around the safety and efficacy of psychedelics.

Cybin is at the forefront of psychedelic research. they’re actively working to develop safe, effective medicines. Those that can help patients find relief from their mental health issues. With its strong scientific team and cutting-edge technology, Cybin is well positioned. They could become a leading player in the fast-growing market for psychedelics.

So, if you’re interested in investing in stocks under $1, Cybin is definitely worth looking into. With its promising pipeline of products and solid financial position, it could be an exciting time. Especially for investors who want to capitalize on this fast- emerging industry.

[/gated-content]

Final Thoughts On the Best Stocks Under $1

If you’re looking for stocks under $1 that have high growth potential, the above are all worth considering. These companies are at the forefront of innovative biotech and pharmaceutical research. There’s a growing demand for new treatments for rare diseases and mental health disorders. And these companies are well-positioned to capitalize on that.